AR104932A1 - Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) - Google Patents
Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)Info
- Publication number
- AR104932A1 AR104932A1 ARP160101696A ARP160101696A AR104932A1 AR 104932 A1 AR104932 A1 AR 104932A1 AR P160101696 A ARP160101696 A AR P160101696A AR P160101696 A ARP160101696 A AR P160101696A AR 104932 A1 AR104932 A1 AR 104932A1
- Authority
- AR
- Argentina
- Prior art keywords
- lys
- ser
- glu
- gly
- leu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente se refiere a compuestos co-agonistas de glucagón y GLP-1 que son útiles en el tratamiento de diabetes tipo 2, obesidad, enfermedad del hígado graso no alcohólica (NAFLD) y/o esteatohepatitis no alcohólica (NASH). Reivindicación 1: Un compuesto de la siguiente fórmula: His-Xaa²-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-Lys-Glu-Phe-Val-Glu-Trp-Leu-Leu-Xaa²⁸-Gly-Gly-Pro-Ser-Ser-Gly caracterizado porque Xaa² es Aib; Xaa²⁸ es Glu o Ser; Lys en la posición 20 es químicamente modificado por conjugación del grupo épsilon-amino de la cadena lateral Lys con un ácido graso C₁₄₋₂₄ mediante (i) un enlace directo o (ii) un enlazador entre la Lys en la posición 20 y el ácido graso C₁₄₋₂₄; y el aminoácido C-terminal es opcionalmente amidado (SEQ ID Nº 2); o una sal del mismo farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182847P | 2015-06-22 | 2015-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104932A1 true AR104932A1 (es) | 2017-08-23 |
Family
ID=56289604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101696A AR104932A1 (es) | 2015-06-22 | 2016-06-08 | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US9938335B2 (es) |
| EP (2) | EP3785724A1 (es) |
| JP (4) | JP6585197B2 (es) |
| KR (2) | KR102034607B1 (es) |
| CN (2) | CN113956348B (es) |
| AR (1) | AR104932A1 (es) |
| AU (1) | AU2016283984B2 (es) |
| CA (1) | CA2987489A1 (es) |
| CL (1) | CL2017003185A1 (es) |
| CO (1) | CO2018000078A2 (es) |
| CR (1) | CR20170534A (es) |
| CY (1) | CY1123591T1 (es) |
| DK (1) | DK3310371T3 (es) |
| DO (1) | DOP2017000303A (es) |
| EA (1) | EA038720B1 (es) |
| EC (1) | ECSP17084280A (es) |
| ES (1) | ES2833458T3 (es) |
| HR (1) | HRP20201881T1 (es) |
| HU (1) | HUE052684T2 (es) |
| IL (4) | IL285231B (es) |
| JO (1) | JO3686B1 (es) |
| LT (1) | LT3310371T (es) |
| MA (2) | MA54407A (es) |
| MD (1) | MD3310371T2 (es) |
| MX (1) | MX380322B (es) |
| MY (1) | MY190210A (es) |
| NZ (1) | NZ737050A (es) |
| PE (2) | PE20231639A1 (es) |
| PH (1) | PH12017502359A1 (es) |
| PL (1) | PL3310371T3 (es) |
| PT (1) | PT3310371T (es) |
| RS (1) | RS61107B1 (es) |
| SI (1) | SI3310371T1 (es) |
| SV (1) | SV2017005594A (es) |
| TN (1) | TN2017000531A1 (es) |
| TW (3) | TWI669309B (es) |
| UA (1) | UA122692C2 (es) |
| WO (1) | WO2016209707A1 (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI669309B (zh) * | 2015-06-22 | 2019-08-21 | 美商美國禮來大藥廠 | 升糖素及ｇｌｐ－１共激動劑化合物 |
| CN109715662B (zh) | 2015-12-23 | 2023-07-21 | 美国安进公司 | 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法 |
| JOP20170153A1 (ar) * | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
| CN108299553B (zh) * | 2017-01-13 | 2021-07-16 | 博瑞生物医药（苏州）股份有限公司 | 胃泌酸调节素修饰物 |
| JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
| WO2018237097A1 (en) | 2017-06-20 | 2018-12-27 | Amgen Inc. | METHOD OF TREATING OR REDUCING METABOLIC DISORDERS USING GASTRIC INHIBITING PEPTIDE RECEPTOR BINDING PROTEINS (GIPR) IN ASSOCIATION WITH GLP-1 AGONISTS |
| EP3642238A1 (en) | 2017-06-21 | 2020-04-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins |
| JP6984923B2 (ja) * | 2017-09-19 | 2021-12-22 | イミュンワーク インク.Immunwork Inc. | アルブミンとの強化された結合親和性を有する医薬構築物 |
| WO2019085772A1 (zh) * | 2017-11-06 | 2019-05-09 | 深圳市图微安创科技开发有限公司 | 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化 |
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI809515B (zh) * | 2017-12-21 | 2023-07-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| WO2019140025A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| EP3882263A4 (en) * | 2018-11-12 | 2022-08-31 | Tianjin Institute Of Pharmaceutical Research Co., Ltd. | GLUCAGON DERIVED PEPTIDE AND USE THEREOF |
| WO2020098657A1 (zh) * | 2018-11-12 | 2020-05-22 | 天津药物研究院有限公司 | 具有双重受体激动作用的胰高血糖素衍生肽及其用途 |
| EP3993823A1 (en) * | 2019-07-01 | 2022-05-11 | MedImmune Limited | Pharmaceutical compositions for glucagon and glp-1 co-agonist peptides |
| CN111423506B (zh) * | 2019-11-08 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种glp-1化合物 |
| KR20220131292A (ko) * | 2020-01-23 | 2022-09-27 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공동-효능제 화합물 |
| CN113336840B (zh) * | 2020-03-02 | 2022-09-23 | 武汉帕肽生物医药有限责任公司 | 订书肽、其制备方法和用途 |
| WO2021182898A1 (ko) * | 2020-03-11 | 2021-09-16 | 애니젠 주식회사 | 신규한 화합물을 포함하는 항당뇨 및 항비만용 조성물 |
| CN111410686B (zh) * | 2020-03-18 | 2021-02-26 | 南京枫璟生物医药科技有限公司 | Glp-1r激活剂的分子改构及其二聚体在治疗代谢病中的应用 |
| CN115315438A (zh) * | 2020-04-10 | 2022-11-08 | 费森尤斯卡比肿瘤学有限公司 | 索玛鲁肽侧链的改进制备方法 |
| CA3175852A1 (en) | 2020-04-29 | 2021-11-04 | Onegene Biotechnology Inc. | Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes |
| IL297976A (en) * | 2020-05-15 | 2023-01-01 | Lilly Co Eli | Extended time action acylated insulin compounds |
| AR122579A1 (es) * | 2020-06-12 | 2022-09-21 | Lilly Co Eli | Proceso para preparar un agonista dual glp-1 / glucagón |
| AU2021308828A1 (en) * | 2020-07-15 | 2023-02-23 | Hanmi Pharm. Co., Ltd. | Therapeutic use of glucagon derivative or conjugate thereof for liver disease |
| WO2022140373A1 (en) * | 2020-12-22 | 2022-06-30 | Eli Lilly And Company | Therapeutic peptide formulations |
| CN112898405B (zh) * | 2021-01-22 | 2023-02-28 | 深圳市图微安创科技开发有限公司 | 多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用 |
| US20240293513A1 (en) * | 2021-06-25 | 2024-09-05 | Innovent Biologics (Suzhou) Co., Ltd. | Use of mazdutide |
| CN116554299A (zh) * | 2021-07-19 | 2023-08-08 | 青岛博睿精创科技有限公司 | 长效glp-1多肽类似物及其制备方法和应用 |
| WO2023016346A1 (zh) * | 2021-08-10 | 2023-02-16 | 南京明德新药研发有限公司 | 含内酰胺桥的多肽化合物 |
| KR20230037391A (ko) * | 2021-09-09 | 2023-03-16 | 애니젠 주식회사 | 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| CN118234743A (zh) * | 2021-11-19 | 2024-06-21 | 深圳市康哲生物科技有限公司 | 含订合钉的多肽及其应用 |
| TW202404996A (zh) | 2022-04-04 | 2024-02-01 | 美商美國禮來大藥廠 | 製備glp-1/升糖素雙重促效劑之方法 |
| WO2023207107A1 (zh) * | 2022-04-29 | 2023-11-02 | 苏州星洲生物科技有限公司 | Glp-1/gcg受体共激动剂、包含其的药物组合物及其用途 |
| JP2025518758A (ja) | 2022-06-01 | 2025-06-19 | イーライ リリー アンド カンパニー | 療法のためのｇｃｇ／ｇｌｐ１コアゴニストを使用する方法 |
| CN119584980A (zh) * | 2022-06-01 | 2025-03-07 | 信达生物制药(苏州)有限公司 | 使用mazdutide的治疗方法 |
| CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
| CN117586373A (zh) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | 一种长效双激动剂化合物 |
| KR20250057847A (ko) | 2022-08-29 | 2025-04-29 | 일라이 릴리 앤드 캄파니 | 경구 전달용 조성물 |
| CN120303283A (zh) * | 2022-10-05 | 2025-07-11 | 伊莱利利公司 | 用于肠降血糖素合成的肽 |
| EP4622998A2 (en) * | 2022-11-21 | 2025-10-01 | Eli Lilly and Company | Process for preparing a gip/glp1 dual agonist |
| CR20250313A (es) | 2023-01-31 | 2025-08-26 | Lilly Co Eli | Agonistas del trirreceptor gip/glp1/gcg y usos de estos |
| WO2024252366A1 (en) * | 2023-06-09 | 2024-12-12 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists |
| WO2025073288A1 (en) * | 2023-10-03 | 2025-04-10 | Innovent Biologics (Suzhou) Co., Ltd. | Methods of treating adolescent obesity |
| CN119912532A (zh) * | 2023-10-30 | 2025-05-02 | 成都奥达生物科技有限公司 | 一种双激动剂化合物 |
| WO2025098464A1 (en) * | 2023-11-10 | 2025-05-15 | Innovent Biologics (Suzhou) Co., Ltd. | Intermediate for preparing glucagon and glp-1 dual agonist and preparation method therefor |
| CN121064327A (zh) * | 2024-06-03 | 2025-12-05 | 信达生物制药(苏州)有限公司 | Gipr、glp1r和/或gcgr的调节剂及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1935839B (zh) * | 1998-12-07 | 2012-06-06 | 益普生制药股份有限公司 | 胰高血糖素样肽-1的类似物 |
| CA2728284C (en) * | 2008-06-17 | 2019-09-10 | Richard D. Dimarchi | Glucagon/glp-1 receptor co-agonists |
| CA2852177A1 (en) * | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
| CN102834108A (zh) * | 2010-01-27 | 2012-12-19 | 印第安纳大学研究及科技有限公司 | 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物 |
| EP2723766A4 (en) | 2011-06-22 | 2015-05-20 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
| EP2729493B1 (en) * | 2011-07-04 | 2020-06-10 | IP2IPO Innovations Limited | Novel compounds and their effects on feeding behaviour |
| US8859491B2 (en) * | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| US9546205B2 (en) * | 2012-09-17 | 2017-01-17 | Imperial Innovations Limited | Peptide analogues of glucagon and GLP1 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| US20160058881A1 (en) | 2013-03-15 | 2016-03-03 | Indiana University Research And Technology Corporation | Prodrugs with prolonged action |
| TWI669309B (zh) * | 2015-06-22 | 2019-08-21 | 美商美國禮來大藥廠 | 升糖素及ｇｌｐ－１共激動劑化合物 |
-
2016
- 2016-06-08 TW TW105118223A patent/TWI669309B/zh active
- 2016-06-08 TW TW109123454A patent/TWI783244B/zh active
- 2016-06-08 AR ARP160101696A patent/AR104932A1/es active IP Right Grant
- 2016-06-08 TW TW107124831A patent/TWI700291B/zh active
- 2016-06-09 JO JOP/2016/0116A patent/JO3686B1/ar active
- 2016-06-16 EP EP20198508.2A patent/EP3785724A1/en active Pending
- 2016-06-16 MA MA054407A patent/MA54407A/fr unknown
- 2016-06-16 UA UAA201712096A patent/UA122692C2/uk unknown
- 2016-06-16 IL IL285231A patent/IL285231B/en unknown
- 2016-06-16 IL IL294099A patent/IL294099B2/en unknown
- 2016-06-16 CN CN202111209577.XA patent/CN113956348B/zh active Active
- 2016-06-16 AU AU2016283984A patent/AU2016283984B2/en active Active
- 2016-06-16 PE PE2022000797A patent/PE20231639A1/es unknown
- 2016-06-16 CA CA2987489A patent/CA2987489A1/en active Pending
- 2016-06-16 TN TNP/2017/000531A patent/TN2017000531A1/en unknown
- 2016-06-16 PL PL16733268T patent/PL3310371T3/pl unknown
- 2016-06-16 KR KR1020177036488A patent/KR102034607B1/ko active Active
- 2016-06-16 PT PT167332683T patent/PT3310371T/pt unknown
- 2016-06-16 MA MA46219A patent/MA46219B1/fr unknown
- 2016-06-16 JP JP2017566081A patent/JP6585197B2/ja active Active
- 2016-06-16 MX MX2017016198A patent/MX380322B/es unknown
- 2016-06-16 EA EA201792562A patent/EA038720B1/ru unknown
- 2016-06-16 SI SI201630939T patent/SI3310371T1/sl unknown
- 2016-06-16 PE PE2017002765A patent/PE20180523A1/es unknown
- 2016-06-16 LT LTEP16733268.3T patent/LT3310371T/lt unknown
- 2016-06-16 CR CR20170534A patent/CR20170534A/es unknown
- 2016-06-16 NZ NZ737050A patent/NZ737050A/en unknown
- 2016-06-16 MD MDE20180406T patent/MD3310371T2/ro unknown
- 2016-06-16 US US15/184,116 patent/US9938335B2/en active Active
- 2016-06-16 ES ES16733268T patent/ES2833458T3/es active Active
- 2016-06-16 HU HUE16733268A patent/HUE052684T2/hu unknown
- 2016-06-16 EP EP16733268.3A patent/EP3310371B1/en active Active
- 2016-06-16 CN CN201680036771.3A patent/CN107735100B/zh active Active
- 2016-06-16 IL IL307657A patent/IL307657A/en unknown
- 2016-06-16 MY MYPI2017704914A patent/MY190210A/en unknown
- 2016-06-16 HR HRP20201881TT patent/HRP20201881T1/hr unknown
- 2016-06-16 WO PCT/US2016/037818 patent/WO2016209707A1/en not_active Ceased
- 2016-06-16 RS RS20201437A patent/RS61107B1/sr unknown
- 2016-06-16 DK DK16733268.3T patent/DK3310371T3/da active
- 2016-06-16 KR KR1020197030220A patent/KR102544419B1/ko active Active
-
2017
- 2017-11-16 IL IL255723A patent/IL255723B/en unknown
- 2017-12-13 CL CL2017003185A patent/CL2017003185A1/es unknown
- 2017-12-15 SV SV2017005594A patent/SV2017005594A/es unknown
- 2017-12-19 PH PH12017502359A patent/PH12017502359A1/en unknown
- 2017-12-19 DO DO2017000303A patent/DOP2017000303A/es unknown
- 2017-12-21 EC ECIEPI201784280A patent/ECSP17084280A/es unknown
-
2018
- 2018-01-05 CO CONC2018/0000078A patent/CO2018000078A2/es unknown
-
2019
- 2019-09-04 JP JP2019161068A patent/JP6985345B2/ja active Active
-
2020
- 2020-11-16 CY CY20201101082T patent/CY1123591T1/el unknown
-
2021
- 2021-11-25 JP JP2021190654A patent/JP7386218B2/ja active Active
-
2023
- 2023-11-13 JP JP2023193059A patent/JP7739384B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR104932A1 (es) | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) | |
| AR131857A2 (es) | Compuestos co-agonistas de gip y glp-1 | |
| AR122964A2 (es) | Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
| ES2606173T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención del cáncer | |
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| ES2540858T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención de cáncer | |
| AR091866A1 (es) | Analogos del glucagon | |
| PE20151770A1 (es) | Compuesto peptidico | |
| PE20142113A1 (es) | Analogos de glucagon | |
| AR106318A1 (es) | Agonistas del receptor de glucagón | |
| AR094181A1 (es) | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon | |
| RU2021134101A (ru) | Модифицированная j-цепь | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| AR086998A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| AR070276A1 (es) | Composicion que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas. formulacion farmaceutica. usos. metodo de preparacion. | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| MD20170055A2 (ro) | Co-agonişti ai receptorilor glucagonului şi GLP-1 | |
| AR098736A1 (es) | Análogos del péptido exendina-4 como agonistas duales del receptor del glp-1 / gip (péptido similar al glucagón tipo 1 / polipéptido insulinotrópico dependiente de glucosa) | |
| PE20141546A1 (es) | Anticuerpos anti-cd134(ox40) y sus usos de los mismos | |
| AR098737A1 (es) | Agonistas duales del receptor de glp-1 / gip | |
| PE20240215A1 (es) | Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo | |
| PE20170087A1 (es) | Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon | |
| PE20121360A1 (es) | Anticuerpos neutralizadores contra el receptor de prolactina | |
| AR120714A1 (es) | Análogos de incretina y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration |